Immunotherapy and chemo before surgery for head and neck cancer
Part of Cancer clinical trials.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with head and neck cancer (squamous cell carcinoma) that can be surgically removed and has not spread far.
- You have not had any prior treatment for this cancer.
- You are in good overall health (able to do daily activities with minimal or no help).
- You are willing to have surgery and follow the treatment plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial compares two immunotherapy drugs (ivonescimab and pembrolizumab) given with standard chemotherapy before and possibly after surgery for advanced head and neck cancer that can be removed. The aim is to see which drug is better at shrinking the tumor and improving outcomes.
This study tests whether giving a combination of immunotherapy (camrelizumab) with either an EGFR antibody or chemotherapy before and after surgery can help treat locally advanced head and neck cancer. It aims to see if this approach improves outcomes compared to standard care.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.